N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications
Dong Wang,Yan Zhang,Qingbo Li,Ao Zhang,Jingxuan Xu,Yu Li,Wen Li,Lin Tang,Fan Yang,Jingyan Meng
DOI: https://doi.org/10.1016/j.biopha.2023.115477
IF: 7.419
2023-09-11
Biomedicine & Pharmacotherapy
Abstract:Cancer therapy resistance (CTR) is the development of cancer resistance to multiple therapeutic strategies, which severely affects clinical response and leads to cancer progression, recurrence, and metastasis. N6-methyladenosine (m6A) has been identified as the most common, abundant, and conserved internal transcriptional alterations of RNA modifications, regulating RNA splicing, translation, stabilization, degradation, and gene expression, and is involved in the development and progression of a variety of diseases, including cancer. Recent studies have shown that m6A modifications play a critical role in both cancer development and progression, especially in reversing CTR. Although m6A modifications have great potential in CTR, the specific molecular mechanisms are not fully elucidated. In this review, we summarize the potential molecular mechanisms of m6A modification in CTR. In addition, we update recent advances in natural products from Traditional Chinese Medicines (TCM) and small-molecule lead compounds targeting m6A modifications, and discuss the great potential and clinical implications of these inhibitors targeting m6A regulators and combinations with other therapies to improve clinical efficacy and overcome CTR.
pharmacology & pharmacy,medicine, research & experimental